Kurs
-0,66%
Likviditet
0,24 MDKK
Kalender
| Est. tid* | ||
| 2025-11-19 | 08:20 | Kvartalsrapport 2025-Q3 |
| 2025-08-15 | 08:20 | Kvartalsrapport 2025-Q2 |
| 2025-05-08 | - | Kvartalsrapport 2025-Q1 |
| 2025-04-14 | - | X-dag ordinarie utdelning BIOPOR 0.00 DKK |
| 2025-04-11 | - | Årsstämma |
| 2025-03-20 | - | Bokslutskommuniké 2024 |
| 2024-11-14 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-15 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-08 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-01 | - | X-dag ordinarie utdelning BIOPOR 0.00 DKK |
| 2024-04-30 | - | Årsstämma |
| 2024-04-04 | - | Bokslutskommuniké 2023 |
| 2023-11-01 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-01 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-10 | - | Kvartalsrapport 2023-Q1 |
| 2023-04-28 | - | X-dag ordinarie utdelning BIOPOR 0.00 DKK |
| 2023-04-27 | - | Årsstämma |
| 2023-03-30 | - | Bokslutskommuniké 2022 |
| 2022-11-23 | - | Extra Bolagsstämma 2022 |
| 2022-11-09 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-17 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-11 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-04 | - | X-dag ordinarie utdelning BIOPOR 0.00 DKK |
| 2022-04-01 | - | Årsstämma |
| 2022-03-10 | - | Bokslutskommuniké 2021 |
| 2021-11-17 | - | Kvartalsrapport 2021-Q3 |
| 2021-11-15 | - | Extra Bolagsstämma 2021 |
| 2021-08-18 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-12 | - | Kvartalsrapport 2021-Q1 |
| 2021-05-03 | - | X-dag ordinarie utdelning BIOPOR 0.00 DKK |
| 2021-04-29 | - | Årsstämma |
| 2021-03-17 | - | Bokslutskommuniké 2020 |
| 2020-11-18 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-19 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-07 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-14 | - | Årsstämma |
| 2020-03-20 | - | X-dag ordinarie utdelning BIOPOR 0.00 DKK |
| 2020-03-11 | - | Bokslutskommuniké 2019 |
| 2019-11-21 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-15 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-09 | - | Kvartalsrapport 2019-Q1 |
| 2019-03-19 | - | X-dag ordinarie utdelning BIOPOR 0.00 DKK |
| 2019-03-18 | - | Årsstämma |
| 2019-02-22 | - | Bokslutskommuniké 2018 |
| 2018-11-08 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-16 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-03 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-16 | - | X-dag ordinarie utdelning BIOPOR 0.00 DKK |
| 2018-04-13 | - | Årsstämma |
| 2018-03-08 | - | Bokslutskommuniké 2017 |
| 2017-11-07 | - | Kvartalsrapport 2017-Q3 |
| 2017-05-04 | - | Kvartalsrapport 2017-Q1 |
| 2017-04-24 | - | X-dag ordinarie utdelning BIOPOR 0.00 DKK |
| 2017-04-21 | - | Årsstämma |
| 2017-03-15 | - | Bokslutskommuniké 2016 |
| 2016-11-03 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-04 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-04 | - | Kvartalsrapport 2016-Q1 |
| 2016-04-15 | - | X-dag ordinarie utdelning BIOPOR 0.00 DKK |
| 2016-04-14 | - | Årsstämma |
| 2016-03-16 | - | Bokslutskommuniké 2015 |
| 2015-11-06 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-10 | - | Kvartalsrapport 2017-Q2 |
| 2015-08-07 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-05 | - | Kvartalsrapport 2015-Q1 |
| 2015-04-13 | - | X-dag ordinarie utdelning BIOPOR 0.00 DKK |
| 2015-04-10 | - | Årsstämma |
| 2015-03-18 | - | Bokslutskommuniké 2014 |
| 2014-11-07 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-08 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-06 | - | Kvartalsrapport 2014-Q1 |
| 2014-04-11 | - | X-dag ordinarie utdelning BIOPOR 0.00 DKK |
| 2014-04-10 | - | Årsstämma |
| 2014-03-19 | - | Bokslutskommuniké 2013 |
| 2013-11-08 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-02 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-07 | - | Kvartalsrapport 2013-Q1 |
| 2013-04-17 | - | X-dag ordinarie utdelning BIOPOR 0.00 DKK |
| 2013-04-16 | - | Årsstämma |
| 2013-03-19 | - | Bokslutskommuniké 2012 |
| 2013-02-26 | - | Extra Bolagsstämma 2013 |
| 2012-11-20 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-23 | - | Kvartalsrapport 2012-Q2 |
| 2012-05-25 | - | Kvartalsrapport 2012-Q1 |
| 2012-04-18 | - | X-dag ordinarie utdelning BIOPOR 0.00 DKK |
| 2012-04-17 | - | Årsstämma |
| 2012-03-19 | - | Bokslutskommuniké 2011 |
| 2011-11-24 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-25 | - | Kvartalsrapport 2011-Q2 |
| 2011-05-25 | - | Kvartalsrapport 2011-Q1 |
| 2011-04-07 | - | Årsstämma |
| 2011-03-17 | - | X-dag ordinarie utdelning BIOPOR 0.00 DKK |
| 2010-04-21 | - | X-dag ordinarie utdelning BIOPOR 0.00 DKK |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Small Cap Copenhagen |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
April 28, 2025
News release
BioPorto A/S to host first quarter 2025 earnings webcast for investors
COPENHAGEN, DENMARK, April 28, 2025 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today that, in connection with the release of its Interim Report for the first quarter 2025, CFO Niels Høy Nielsen will present financial results for Q1 2025 at a webcast for investors on May 8 at 1:00 PM.
Registration for the presentation is now open, and participants can submit questions in advance. Please register at the following link: https://www.inderes.dk/videos/bioporto-praesentation-af-q1-2025
For further information, please contact:
Hanne S. Foss, Head of Investor Relations, BioPorto A/S, investor@bioporto.com, C: +45 26368918
About BioPorto
BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.
The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide.
BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com.